Medical School, College of Health and Medicine, Australian National University, Canberra, Australia; Department of Head and Neck Surgery, Sydney Head and Neck Cancer Institute, Chris O'Brien Lifehouse, Sydney, New South Wales, Australia; Department of Head and Neck Surgery, The Canberra Hospital, Canberra, Australia.
Department of Tissue Pathology and Diagnostic Oncology, NSW Health Pathology, Royal Prince Alfred Hospital, Sydney, Australia; Sydney Medical School, The University of Sydney, Sydney, Australia.
Oral Oncol. 2020 Dec;111:104855. doi: 10.1016/j.oraloncology.2020.104855. Epub 2020 Aug 21.
We aimed to determine if the number of nodal metastases is an independent predictor of survival in HNcSCC, whether it provides additional prognostic information to the AJCC N and TNM stage and identify optimal cut-points for risk stratification.
Retrospective multi-institutional cohort study of patients with parotid and/or cervical nodal metastases from HNcSCC treated with curative intent by surgery ± adjuvant therapy. The impact of number of nodal metastases on disease-specific and overall survival was assessed using multivariate Cox regression. Optimal cut-points for prognostic discrimination modelled using the AIC, BIC, C-index and PVE.
The study cohort included 1128 patients, with 962 (85.3%) males, median age of 72.9 years (range: 18-100 years) and median follow-up 3.4 years. Adjuvant radiotherapy was administered to 946 (83.9%) patients. Based on objective measures of model performance, number of nodal metastases was classified as 1-2 (N = 816), 3-4 (N = 162) and ≥5 (N = 150) nodes. In multivariate analyses, the risk of disease-specific mortality progressively increased with 3-4 nodes (HR, 1.58; 95% CI: 1.03-2.42; p = 0.036) and ≥5 nodes (HR, 2.91; 95% CI: 1.99-4.25; p < 0.001) with similar results for all-cause mortality. This simple categorical variable provided superior prognostic information to the TNM stage.
Increasing number of nodal metastases is an independent predictor of mortality in HNcSCC, with categorization as 1-2, 3-4 and ≥5 nodes optimizing risk stratification and providing superior prognostic information to TNM stage. These findings may aid in the development of future staging systems as well as identification of high-risk patients in clinical trials.
本研究旨在确定淋巴结转移数量是否为头颈部鳞癌(HNcSCC)患者生存的独立预测因素,是否能为 AJCC N 分期和 TNM 分期提供额外的预后信息,并确定最佳风险分层切点。
本研究为回顾性多机构队列研究,纳入了接受以手术为主的根治性治疗、伴或不伴颈部淋巴结转移的腮腺和/或颈部 HNcSCC 患者。采用多变量 Cox 回归评估淋巴结转移数量对疾病特异性和总生存的影响。采用 AIC、BIC、C 指数和 PVE 对预后判别最优切点进行建模。
本研究队列纳入了 1128 例患者,其中 962 例(85.3%)为男性,中位年龄为 72.9 岁(范围:18-100 岁),中位随访时间为 3.4 年。946 例(83.9%)患者接受了辅助放疗。基于模型性能的客观指标,淋巴结转移数量被分为 1-2 枚(N=816)、3-4 枚(N=162)和≥5 枚(N=150)。多变量分析显示,与 3-4 枚淋巴结转移相比,3-4 枚和≥5 枚淋巴结转移患者疾病特异性死亡风险逐渐增加(HR 分别为 1.58、95%CI:1.03-2.42、p=0.036;HR 分别为 2.91、95%CI:1.99-4.25、p<0.001),所有原因死亡的结果相似。这一简单的分类变量为 TNM 分期提供了更优的预后信息。
淋巴结转移数量的增加是 HNcSCC 患者死亡的独立预测因素,将其分为 1-2、3-4 和≥5 枚可优化风险分层,并为 TNM 分期提供更优的预后信息。这些发现可能有助于未来分期系统的制定,并在临床试验中识别高危患者。